US issues report on actions to strengthen Medicare Telehealth

As the pandemic nears an end, the federal government has signaled that telehealth regulatory compliance is returning quickly, and it’s time to think once again about privacy, security, and quality when delivering care via telemedicine. Importantly, on Sept. 26, 2022, the U.S. Government Accountability Office (GAO) released GAO-22-104454, titled “Medicare Telehealth: Actions Need to Strengthen Oversight and Help Providers Educate Patients on Privacy and Security Risks.”

The GAO report notes that in 2020, the “use of telehealth services rose tenfold,” with 53 million telehealth visits during the last three quarters of 2020. Only 5 million telehealth visits were recorded in the same period in 2019. The number of in-person services dropped by 25 percent. According to the GAO report, mental health and behavioral health providers delivered approximately half of their services via telehealth between April 2020 and December 2020.

Source

Related News

All News

Willum Þór: The question remains if our healthcare system is sustainable

On January 1st, Iceland took over the Presidency of the Nordic Council of Ministers. This intergovernmental organisation plays an important role in promoting innovations, health data integration, and cooperation between all major stakeholders in the Nordic healthcare. The Icelandic Health Minister elaborates on his vision to future health in the Nordic region, the Nordic strengths, Iceland’s plans for the Presidency with regards to health innovations, and the coming collaboration with Copenhagen Institute for Futures Studies

CIFS ran an all-day session at the Week of Health and Innovation (WHINN) in Odense

Copenhagen Institute for Futures Studies ran an all-day session at the annual Week of Health and Innovation (WHINN) in Odense, Denmark. CIFS’ program attracted over 40 experts from health and data organisations. We presented strategic foresight and futures studies in the health sector, concepts that are used to reimagine the future of the health sector, such as the Humanome and decentralised clinical trials. Also, we had a panel discussion on the newly started Phase V project on decentralised clinical trials, where CIFS is a contributing partner